Fosphenytoin - Sedor Pharmaceuticals

Drug Profile

Fosphenytoin - Sedor Pharmaceuticals

Alternative Names: LGD-461

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class Antiepileptic drugs; Hydantoins; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Status epilepticus

Most Recent Events

  • 08 Dec 2015 Captisol-enabled™ Fosphenytoin licensed to RODES in USA
  • 15 Feb 2011 Fosphenytoin - CyDex Pharmaceuticals is available for licensing as of 15 Feb 2011. http://cydexpharma.com
  • 15 Feb 2011 Phase-III clinical trials in Status epilepticus in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top